meRfi®-GM
Methicillin-resistant Staphylococcus aureus (MRSA) Infection
Welcome to meRfi-GM!
meRfi-GM provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.
Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.
Start your free trial and transform your understanding of the gut microbiota today!
Navigation
Contents
Bacteremia caused by Staphylococcus aureus is common. Cases caused by methicillin-resistant S. aureus (MRSA) are particularly formidable and often lethal. The mortality associated with MRSA bacteremia has not significantly decreased over the past couple of decades and concerns regarding efficacy and toxicity of standard therapy highlight the need for novel agents and new therapeutic approaches.
Burgin et al. 2022 Expert Opinion on Investigational Drugs 31(3): 263-279
One pathogen-drug combination, methicillin-resistant S aureus, caused more than 100 000 deaths attributable to AMR in 2019
Murray et al. 2022 Lancet 399: 629-5…
References (Sources)
- Innovative therapies for acute bacterial skin and skin-structure infections (ABSSSI) caused by methicillin-resistant Staphylococcus aureus: advances in phase I and II trials
- Multidrug-Resistant Bacterial Infections in U.S. Hospitalized Patients, 2012–2017
- Multivalent human antibody-centyrin fusion protein to prevent and treat Staphylococcus aureus infections
- Pneumonia caused by methicillin-resistant Staphylococcus aureus
- Staphylococcus aureus alpha-Hemolysin Activates the NLRP3-Inflammasome in Human and Mouse Monocytic Cells